NIPBL::NACC1 Fusion Hepatic Carcinoma.
Hissong E, Al Assaad M, Bal M, Reed KA, Fornelli A, Levine MF, Gundem G, Semaan A, Orr CE, Sakhadeo U, Manohar J, Sigouros M, Wilkes D, Sboner A, Montgomery EA, Graham RP, Medina-Martínez JS, Robine N, Fang JM, Choi EK, Westerhoff M, Delgado-de la Mora J, Caudell P, Yantiss RK, Papaemmanuil E, Elemento O, Sigel C, Jessurun J, Mosquera JM.
Am J Surg Pathol. 2024 Feb 1;48(2):183-193. doi: 10.1097/PAS.0000000000002159. Epub 2023 Dec 4.
In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma.
Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L.
Front Immunol. 2021 May 7;12:650486. doi: 10.3389/fimmu.2021.650486. eCollection 2021.
In situ Thermal-Responsive Magnetic Hydrogel for Multidisciplinary Therapy of Hepatocellular Carcinoma.
Yan X, Sun T, Song Y, Peng W, Xu Y, Luo G, Li M, Chen S, Fang WW, Dong L, Xuan S, He T, Cao B, Lu Y.
Nano Lett. 2022 Mar 23;22(6):2251-2260. doi: 10.1021/acs.nanolett.1c04413. Epub 2022 Mar 7.
A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma.
Yang J, He Q, Lu F, Chen K, Ni Z, Wang H, Zhou C, Zhang Y, Chen B, Bo Z, Li J, Yu H, Wang Y, Chen G.
Gut Microbes. 2023 Jan-Dec;15(1):2201159. doi: 10.1080/19490976.2023.2201159.
Intratumoural microbiome can predict the prognosis of hepatocellular carcinoma after surgery.
Sun L, Ke X, Guan A, Jin B, Qu J, Wang Y, Xu X, Li C, Sun H, Xu H, Xu G, Sang X, Feng Y, Sun Y, Yang H, Mao Y.
Clin Transl Med. 2023 Jul;13(7):e1331. doi: 10.1002/ctm2.1331.
CircTTC13 promotes sorafenib resistance in hepatocellular carcinoma through the inhibition of ferroptosis by targeting the miR-513a-5p/SLC7A11 axis.
Zhang Y, Yao R, Li M, Fang C, Feng K, Chen X, Wang J, Luo R, Shi H, Chen X, Zhao X, Huang H, Liu S, Yin B, Zhong C.
Mol Cancer. 2025 Jan 27;24(1):32. doi: 10.1186/s12943-024-02224-3.
In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma.
Zheng Y, Xu M, Zeng D, Tong H, Shi Y, Feng Y, Zhang X.
Diagn Pathol. 2022 Jan 16;17(1):11. doi: 10.1186/s13000-022-01194-8.
MiR-126 in Hepatocellular Carcinoma and Cholangiocellular Carcinoma: A Reappraisal with an in situ Detection of miR-126.
Zailaie SA, Sergi CM.
Ann Clin Lab Sci. 2022 Jan;52(1):73-85.
NRIR promotes immune escape in hepatocellular cancer by regulating IFNgamma-induced PD-L1 expression.
Zhou Y, Wang J, Chen Y, Lin W, Zhou R, Zhao L, Wang H.
J Adv Res. 2025 Dec;78:423-434. doi: 10.1016/j.jare.2025.02.034. Epub 2025 Feb 27.
Acid-responsive engineered bacteria with aberrant In-Situ anti-PD-1 expression for post-ablation immunotherapy of hepatocellular carcinoma.
Li Y, Wang X, Ye F, Hong X, Chen Y, Huang J, Liu J, Huang X, Liang L, Guo Y, Shi F, Zhu K, Lin L, Huang W.
Biomed Pharmacother. 2025 May;186:118046. doi: 10.1016/j.biopha.2025.118046. Epub 2025 Apr 9.
